HDAC inhibitors (HDACIs), which can be used to kill cancer cells through
inhibiting histone deacetylase activity or altering the structure of chromatin, have
emerged as efficacious agents in the treatment of cancer. With SAHA, FK228, belinostat and panobinostat approved by the
FDA, displaying satisfying activity in both haematological and solid tumors of various tissues, efforts to create selective
HDACIs have been attracted attention over the past several years. Herein, we mainly review the progress of selective HDAC
inhibitors including class-selective and isoform-selective HDAC inhibitors.